Table VI.
Joint effect of NAT and CYP1A2*1F on risk of pancreatic cancer
| Genotype | Case/Con *AOR (95% CI) | Case/Con AOR (95%CI) | |||
|---|---|---|---|---|---|
| NAT1 | CYP1A2*1F | Never smokers | Ever smokers | ||
| Reference | AA/AC | 30/45 | 1.0 | 47/49 | 1.0 |
| Reference | CC | 33/58 | 0.7 (0.4–1.5) | 69/57 | 1.1 (0.6–1.9) |
| Rapid | AA/AC | 17/24 | 1.3 (0.6–2.9) | 27/29 | 1.0 (0.5–1.9) |
| Rapid | CC | 28/15 | 2.9 (1.2–6.9) | 43/29 | 1.5 (0.8–2.8) |
| Male | Female | ||||
| Reference | AA/AC | 49/49 | 1.0 | 28/48 | 1.0 |
| Reference | CC | 59/71 | 0.7 (0.4–1.3) | 43/48 | 1.3 (0.6–2.7) |
| Rapid | AA/AC | 22/28 | 0.9 (0.4–1.8) | 22/28 | 1.5 (0.7–3.3) |
| Rapid | CC | 44/29 | 1.5 (0.8–2.9) | 27/18 | 2.5 (1.1–5.7) |
| NAT1 | NAT2 | Never smokers | Ever smokers | ||
| Reference | Rapid | 19/33 | 1.0 | 35/37 | 1.0 |
| Reference | Slow | 40/63 | 1.1 (0.5–2.4) | 72/67 | 1.3 (0.7–2.4) |
| Rapid | Rapid | 26/21 | 2.7 (1.1–6.5) | 32/27 | 1.3 (0.6–2.8) |
| Rapid | Slow | 20/16 | 2.4 (1.0–6.1) | 34/27 | 1.4 (0.7–2.9) |
| Male | Female | ||||
| Reference | Rapid | 33/39 | 1.0 | 21/33 | 1.0 |
| Reference | Slow | 65/75 | 1.0 (0.6–1.9) | 47/61 | 1.5 (0.7–3.3) |
| Rapid | Rapid | 31/28 | 1.2 (0.6–2.6) | 27/23 | 2.5 (1.1–6.1) |
| Rapid | Slow | 30/25 | 1.5 (0.7–3.1) | 24/21 | 2.2 (0.9–5.5) |
*
Adjusted for age, diabetes, pancreatitis, ethanol intake (all as categorical variables), and smoking status (in comparisons by sex).